Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 17
2013 22
2014 40
2015 34
2016 27
2017 45
2018 33
2019 46
2020 79
2021 62
2022 83
2023 70
2024 34

Text availability

Article attribute

Article type

Publication date

Search Results

529 results

Results by year

Filters applied: . Clear all
Page 1
The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort.
Zijlker LP, Chen H, Spillane AJ, Gonzalez M, Pennington TE, Menzies AM, Lo SN, Ferguson P, Rawson R, Colebatch AJ, Stretch JR, Thompson JF, Ch'ng S, Nieweg O, Shannon KF, Long GV, Scolyer RA, Saw RPM, van Akkooi ACJ. Zijlker LP, et al. Among authors: long gv. Ann Surg Oncol. 2024 May 18. doi: 10.1245/s10434-024-15274-0. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38762644
ASO Visual Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort.
Zijlker LP, Chen H, Spillane AJ, Gonzalez M, Pennington TE, Menzies AM, Lo SN, Ferguson P, Rawson R, Colebatch AJ, Stretch JR, Thompson JF, Ch'ng S, Nieweg O, Shannon KF, Long GV, Scolyer RA, Saw RPM, van Akkooi ACJ. Zijlker LP, et al. Among authors: long gv. Ann Surg Oncol. 2024 May 17. doi: 10.1245/s10434-024-15348-z. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38758487 No abstract available.
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma.
Menzies AM, Lo SN, Saw RPM, Gonzalez M, Ch'ng S, Nieweg OE, Shannon KF, Ferguson PM, Lee J, Emmett L, Kapoor R, Rawson RV, Stretch JR, Thompson JF, Spillane AJ, Rizos H, Scolyer RA, Long GV. Menzies AM, et al. Among authors: long gv. Ann Oncol. 2024 May 14:S0923-7534(24)00141-8. doi: 10.1016/j.annonc.2024.05.002. Online ahead of print. Ann Oncol. 2024. PMID: 38754780
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.
Pires da Silva I, Li I, Ugurel S, Serra-Bellver P, Andhale A, Burnette H, Aya F, Conway JW, Braden J, Carlino MS, Menzies AM, Weichenthal M, Mohr P, Gutzmer R, Arance AM, Johnson DB, Lorigan P, Schadendorf D, Lo SN, Long GV. Pires da Silva I, et al. Among authors: long gv. Eur J Cancer. 2024 May 7;205:114101. doi: 10.1016/j.ejca.2024.114101. Online ahead of print. Eur J Cancer. 2024. PMID: 38735161
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.
Menzies AM, Long GV, Kohn A, Tawbi H, Weber J, Flaherty K, McArthur GA, Ascierto PA, Pfluger Y, Lewis K, Tsai KK, Hamid O, Prenen H, Fein L, Wang E, Guenzel C, Zhang F, Kleha JF, di Pietro A, Davies MA. Menzies AM, et al. Among authors: long gv. Neurooncol Adv. 2024 Mar 18;6(1):vdae033. doi: 10.1093/noajnl/vdae033. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38725995 Free PMC article.
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.
Versluis JM, Blankenstein SA, Dimitriadis P, Wilmott JS, Elens R, Blokx WAM, van Houdt W, Menzies AM, Schrage YM, Wouters MWJM, Sanders J, Broeks A, Scolyer RA, Suijkerbuijk KPM, Long GV, Akkooi ACJV, Blank CU. Versluis JM, et al. Among authors: long gv. J Immunother Cancer. 2024 Apr 27;12(4):e008125. doi: 10.1136/jitc-2023-008125. J Immunother Cancer. 2024. PMID: 38677880 Free PMC article.
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.
Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, Coffin R, de Baere T, de Gruijl TD, Fury M, Goldmacher G, Harrington KJ, Kaufman H, Kelly CM, Khilnani AD, Liu K, Loi S, Long GV, Melero I, Middleton M, Neyns B, Pinato DJ, Sheth RA, Solomon SB, Szapary P, Marabelle A. Luke JJ, et al. Among authors: long gv. J Immunother Cancer. 2024 Apr 18;12(4):e008378. doi: 10.1136/jitc-2023-008378. J Immunother Cancer. 2024. PMID: 38641350 Free PMC article.
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
Bai X, Shaheen A, Grieco C, d'Arienzo PD, Mina F, Czapla JA, Lawless AR, Bongiovanni E, Santaniello U, Zappi H, Dulak D, Williamson A, Lee R, Gupta A, Li C, Si L, Ubaldi M, Yamazaki N, Ogata D, Johnson R, Park BC, Jung S, Madonna G, Hochherz J, Umeda Y, Nakamura Y, Gebhardt C, Festino L, Capone M, Ascierto PA, Johnson DB, Lo SN, Long GV, Menzies AM, Namikawa K, Mandala M, Guo J, Lorigan P, Najjar YG, Haydon A, Quaglino P, Boland GM, Sullivan RJ, Furness AJS, Plummer R, Flaherty KT. Bai X, et al. Among authors: long gv. EClinicalMedicine. 2024 Mar 27;71:102564. doi: 10.1016/j.eclinm.2024.102564. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38572079 Free PMC article. No abstract available.
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis.
Stassen RC, Maas CCHM, van der Veldt AAM, Lo SN, Saw RPM, Varey AHR, Scolyer RA, Long GV, Thompson JF, Rutkowski P, Keilholz U, van Akkooi ACJ, Verhoef C, van Klaveren D, Grünhagen DJ. Stassen RC, et al. Among authors: long gv. Lancet Oncol. 2024 Apr;25(4):509-517. doi: 10.1016/S1470-2045(24)00076-7. Lancet Oncol. 2024. PMID: 38547894
529 results